MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Blueprint Medicines Corp

Gesloten

SectorGezondheidszorg

129.22 -0.1

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

129.22

Max

129.22

Belangrijke statistieken

By Trading Economics

Inkomsten

50M

496K

Verkoop

3M

149M

EPS

-0.294

Winstmarge

0.332

Werknemers

682

EBITDA

-14M

-41M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+0.97% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

2.6B

8.4B

Vorige openingsprijs

129.32

Vorige sluitingsprijs

129.22

Nieuwssentiment

By Acuity

33%

67%

94 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Blueprint Medicines Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

2 jun 2025, 09:17 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 jun 2025, 05:31 UTC

Acquisities, Fusies, Overnames

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

18 jul 2025, 05:00 UTC

Acquisities, Fusies, Overnames

Press Release: Sanofi Completes Acquisition Of Blueprint Medicines >SAN.FR

2 jun 2025, 13:50 UTC

Winsten
Acquisities, Fusies, Overnames

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 10:50 UTC

Acquisities, Fusies, Overnames

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 jun 2025, 10:05 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 jun 2025, 05:06 UTC

Acquisities, Fusies, Overnames

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 jun 2025, 05:06 UTC

Acquisities, Fusies, Overnames

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 jun 2025, 05:05 UTC

Acquisities, Fusies, Overnames

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 jun 2025, 05:05 UTC

Acquisities, Fusies, Overnames

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 jun 2025, 05:04 UTC

Acquisities, Fusies, Overnames

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 jun 2025, 05:04 UTC

Acquisities, Fusies, Overnames

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 jun 2025, 05:03 UTC

Acquisities, Fusies, Overnames

Sanofi to Buy Blueprint Medicines Corporation

2 jun 2025, 05:02 UTC

Acquisities, Fusies, Overnames

Sanofi to Acquire Blueprint Medicines Corporation

Peer Vergelijking

Prijswijziging

Blueprint Medicines Corp Prognose

Koersdoel

By TipRanks

0.97% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 130.71 USD  0.97%

Hoogste 135 USD

Laagste 129 USD

Gebaseerd op 18 Wall Street-analisten die 12-maands prijsdoelen bieden voor Blueprint Medicines Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

18 ratings

2

Buy

16

Hold

0

Sell

Technische score

By Trading Central

87.66 / 99.25Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Strong Bullish Evidence

Sentiment

By Acuity

94 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.